Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

被引：0
|
作者：
Sun, Hui-Chuan
Zhu, Xiao-Dong
Wang, Kui
Xue, Hui
Yang, Ning
Yang, Ying-Cheng
Chen, Yong-Jun
Ye, Feng
Kuang, Ming
Shen, Shun-Li
Huang, Cheng
机构：
[1] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[3] Naval Med Univ, Dept Hepat Surg 2, Eastern Hepatobiliary Surg Hosp, Affiliated Hosp 3, Shanghai, Peoples R China
[4] Naval Med Univ, Dept Hepat Surg 5, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreatobiliary Surg, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial
    Liu, Dongming
    Mu, Han
    Liu, Changfu
    Zhang, Weihao
    Cui, Yunlong
    Wu, Qiang
    Zhu, Xiaolin
    Fang, Feng
    Zhang, Wei
    Xing, Wenge
    Li, Qiang
    Song, Tianqiang
    Lu, Wei
    Li, Huikai
    NEOPLASMA, 2023, 70 (06) : 811 - 818
  • [42] Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING)
    Tan, Li
    Xu, Lixia
    Shen, Shun-Li
    Li, Dongming
    Hua, Yunpeng
    Li, Shaoqiang
    Liang, Lijian
    He, Qiang
    Zhou, Qi
    Xie, Wenxuan
    Chen, Zebin
    Wu, Jian
    Li, Jiaping
    Fan, Wenzhe
    Zhuang, Wenquan
    Chen, Lili
    Feng, Shiting
    Peng, Sui
    Wang, Jiping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)
    Adra, Nabil
    Ammakkanavar, Natraj
    Radovich, Milan
    Vaughn, David J.
    Albany, Costantine
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial
    Zhou, X.
    Zhu, H.
    Gao, H.
    Niu, Z.
    Liu, M.
    Wang, H.
    Kong, X.
    Ma, C.
    Yang, F.
    Hao, Y.
    Zhang, S.
    Lu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1489 - S1489
  • [45] Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.
    Lan, Chunyan
    Yang, Xielan
    Zhao, Jing
    Zheng, Min
    Yang, Fan
    Xie, Zhiwen
    Wu, Xiaoliu
    Yang, Hongying
    Wang, Wenyan
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
    Vogel, A.
    Saborowski, A.
    Siegler, G. M.
    Siebler, J.
    Lindig, U.
    Schultheiss, M.
    Mueller, T.
    Simon, H.
    Joeckel, C.
    Muller, D. W.
    Al-Batran, S-E.
    De Toni, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S598 - S598
  • [47] The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
    Qiao, Qian
    Han, Chun
    Ye, Sisi
    Li, Juan
    Shao, Guoliang
    Bai, Yuxian
    Xu, Aibing
    Sun, Meili
    Wang, Wei
    Wu, Jian
    Huang, Ming
    Song, Lijie
    Huang, Luke
    Liu, Ting
    Liu, Wei
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Michelle
    Bai, Li
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
    Feng, Zizhen
    Curti, Brendan D.
    Quinn, David I.
    Strother, John M.
    Chen, Zunqiu
    Agnor, Rebecca
    Beer, Tomasz M.
    Ryan, Christopher W.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 415 - 422
  • [49] Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
    Li, Guangxin
    Shu, Bin
    Zheng, Zhuozhao
    Yin, Hongfang
    Zhang, Chen
    Xiao, Ying
    Yang, Yanmei
    Yan, Zhe
    Zhang, Xiaofei
    Yang, Shizhong
    Li, Gong
    Dong, Jiahong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Kim, Sung Hyun
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 715 - 715
12345